Objective: The fat mass and obesity-associated gene (FTO) participates in the control of postnatal weight gain. We assessed whether FTO is expressed in human placenta and whether such expression relates to prenatal weight gain and to the rs9939609 single nucleotide polymorphism (SNP) in FTO. Design and subjects: In a birth cohort study, placentas from women (n ¼ 147) with an uncomplicated, singleton, term pregnancy were weighed at delivery. Real-time PCR was used to study, in placental tissue, the expression of FTO and of housekeeping genes (TATA box binding protein and succinate dehydrogenase complex, subunit A) and to genotype the rs9939609 SNP in FTO. Weights and lengths of the newborns were measured; circulating insulin and insulin-like growth factor-I (IGF-I) were quantified in cord blood. Results: FTO was highly expressed in placenta and was associated with increased fetal weight and length (Po0.001 to Po0.0001). Maternal parity showed an interaction (Po0.001) in the association between placental FTO expression and placental weight. Placental FTO mRNA expression was associated with increased fetal-to-placental weight ratio (Po0.005) in infants from primiparous women, and was associated with increased fetal weight and length and placental weight (Po0.001 to Po0.0001) in infants from nonprimiparous women. These associations were not explained by either cord insulin or IGF-I. Placental FTO expression was unrelated to placental FTO rs9939609 SNP Conclusion: FTO is expressed in the human placenta. In a maternal parity-dependent manner, placental FTO may participate either in the control of fetal weight gain or in the partitioning between placental and fetal growth.
Introduction
Size at birth and early infancy growth are known to predict long-term risks for obesity, type 2 diabetes and cardiovascular disease. 1 A genome-wide search for obesity and type 2 diabetessusceptibility genes identified several variants in the fat mass-and obesity-associated (FTO) gene region on chromosome 16q12.2, which were strongly associated with obesityrelated traits and increased the risk for this disease. [2] [3] [4] [5] [6] [7] The human FTO is widely expressed in both fetal and adult tissues, including mesenteric fat, pancreas, liver and adipose tissue, with the highest concentration found in the brain, specifically in the hypothalamus. 2, 8 Obese subjects show increased levels of subcutaneous adipose tissue FTO mRNA compared with non-obese subjects. 9 FTO has been described as an apparently Fe(II)-and 2-oxoglutarate-dependent oxygenase that might operate as a DNA demethylase and may have an important function in human energy homeostasis. 10, 11 Although a large number of reports provide evidence suggesting that FTO is associated with the control of food intake, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] others have suggested that FTO may regulate energy expenditure 22 and lipolysis. 7, 9 The influence of FTO on body composition and on the risk of obesity is observed as early as in childhood 2, 23, 24 The common rs9939609 single nucleotide polymorphism (SNP) in FTO was associated with weight and ponderal index and with total, truncal and abdominal fat mass at age 2 weeks. 25 It was recently shown that FTO is involved in processes connected to growth regulation, as FTO-deficient mice experienced reduced size and body weight compared wiith wild-type animals. 22 A specific role of FTO in prenatal growth, however, was not identified, as FTO-deleted mice showed postnatal but not prenatal growth restriction. Fetal growth is a complex process that depends on the genotype and epigenotype of the fetus, the availability of nutrients and oxygen to the fetus and a variety of growth factors and proteins of maternal and fetal/placental origin. 26 Our aim in this study was to assess whether FTO is expressed in human placenta and whether such expression correlates with prenatal weight gain and to the rs9939609 SNP in FTO.
Patients and methods

Study population and ethics
Subjects were Caucasian women with singleton pregnancies included in a population-based birth cohort study of cardiovascular risk factors in children. Cross-sectional data at birth are presented in this report.
Subjects were consecutively recruited among those seen at the prenatal primary care clinics in Alt Empordà, a region in Northern Spain. Inclusion criteria were (1) uncomplicated pregnancy and parturition (no major medical, surgical or obstetrical complications); (2) delivery of a healthy term (after 37-42 weeks of gestation) neonate. Women with multiple fetuses, diabetes mellitus, preeclampsia and fetal malformations or asphyxia were excluded. A total of n ¼ 147 mother-newborn pairs were included in the study.
The protocol was approved by the Institutional Review Board of Dr Josep Trueta Hospital. Informed written consent was obtained from the women.
Assessments and samples
The mothers were healthy women in whom close prenatal follow-up, consisting of protocolized clinical exams, ultrasonograms and laboratory tests (urine and blood), were performed. Information on maternal socio-demographic, medical and reproductive characteristics, labor and delivery characteristics, as well as anthropometric measurements was abstracted from standardized medical records. Gestational age was based on the last menstrual period and, when possible, was confirmed by ultrasound examination conducted before 20 weeks gestation. Maternal weight and height were assessed at delivery.
Neonates were studied within 24 h of delivery. Weight and length were measured, respectively, using a calibrated scale for weight and a standardized metal measuring board.
Gestational age-and sex-adjusted standard deviation scores for birth weight and length were calculated using regional normative data. 27 Venous cord blood was collected at the time of delivery for measurement of insulin and insulin-like growth factor-I (IGF-I).
Placentas from the studied women were collected and weighed immediately after delivery. Biopsies were placed in cryotubes containing RNAlater (Qiagen Inc., Valencia, CA, USA) at a final concentration of 10 ml mg À1 of tissue and stored at À80 1C.
Analytical method, placental gene expression and genotyping
Cord blood insulin and IGF-I were measured in duplicate by immunochemiluminiscence (IMMULITE 2000, Diagnostic Products, Los Angeles, CA, USA). The lower detection limit for insulin was 0.4 mU ml
À1
. The lower detection limit for IGF-I was 25 ng ml
; the intra-and inter-assay coefficients of variation for both insulin and IGF-I were o10%.
Thirty milligrams of placental tissue from stored biopsies were cut and weighed. The weighed samples were homogenized using a Tissue Tearor (Biospec Products Inc., Bartlesville, OK, USA). Total RNA was extracted by using the RNeasy Fibrous Mini kit (Qiagen Inc.), following the standard protocol including DNase. Total RNA was eluted from the columns in 50 ml of sterile water and aliquoted for storage at À80 1C. Total RNA concentration was calculated by determining absorbance at 260 nm (Spectramax Plus 384 spectrophotometer, Molecular Devices, Sunnyvale, CA, USA). Protein contamination was excluded in analyses of A260/A280 ratios.
One microgram of RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to manufacturer's instructions. Real-time PCR was performed in duplicate on 25 ml mixtures, containing 4 ng ml À1 of template cDNA, 12. Placental FTO and fetal growth J Bassols et al
Genomic DNA was purified from placental tissue using QIAGEN QIAm kits (Qiagen Inc.) and quantified by means of a spectrophotometer (GeneQuant, GE Health Care, Piscataway, NJ, USA). One hundred nanograms of DNA were used for PCR amplification. The FTO SNP (rs9939609) was genotyped by means of an allelic discrimination assay using an ABI Prism 7000 sequence detector and TaqMan technology (Applied Biosystems). The reaction was performed in a final volume of 25 ml. DNA was amplified after 50 cycles with an initial denaturation of 10 min at 95 1C. The cycle program consisted of 15 s denaturation at 92 1C and 1 min annealing and extension at 60 1C. Positive and negative controls, which were correctly identified, 25 were included in all reactions. The population studied was in Hardy-Weinberg equilibrium. Successful genotyping was accomplished in 98% of subjects.
Statistical analysis
Statistical analyses were performed using SPSS statistical package version 12.0 (SPSS, Chigago, IL, USA). Descriptive results of continuous variables are expressed as mean±s.d. for Gaussian variables and as median and interquartile range for non-Gaussian variables. Parameters that did not fulfill normal distribution were log-transformed for subsequent analyses. The relations between variables were explored by simple correlation and stepwise multiple regression analyses. Levels of statistical significance were set at Po0.05. Within the number of patients included, the study had an 80% power to detect a significant correlation between placental FTO expression and fetal weight with a Pearson correlation coefficient of at least 0.30 in the study subgroups.
Results
Placental FTO expression
Real-time PCR analysis of term placentas demonstrated the presence of FTO in all the study samples. Housekeeping genes (TBP and SDHA) were used as controls for stability of the assay and relative quantification. The Ct value for FTO was 27.19 ± 2.01, and those for TBP and SDHA were 28.48 ± 2.50 and 28.30 ± 2.48, indicating that human placenta expresses considerable amount of FTO.
Placental FTO is related to fetal weight Table 1 shows the clinical and biochemical assessments in the studied subjects and in subgroups thereof according to maternal parity (see below).
Placental FTO expression was associated with increased fetal weight and length (Po0.005 to Po0.0001; Table 2 ); these associations proved to be independent from maternal and fetal characteristics (Table 3) .
Placental FTO is related to placental weight in a maternal parity-dependent manner An interaction was evident for maternal parity in the association between placental FTO expression and placental weight (Po0.001). In primiparous pregnancies, smaller placentas expressed more FTO per tissue weight; in nonprimiparous (Table 2) . Infants from nonprimiparous women showed increased weight (Po0.01), fetal-to-placental weight ratio (Po0.05), higher cord IGF-I levels (Po0.01) and higher placental FTO mRNA expression (Po0.05) than infants from primiparous mothers ( Table 1) .
Further analysesFtaking into account the differential expression of placental FTO according to maternal parityF showed that the expression of this gene in placenta was associated with increased fetal-to-placental weight ratio (Po0.005, Tables 2 and 3) in primiparous women, and was associated with increased fetal weight and length and placental weight (Po0.001 to Po0.0001; Tables 2 and 3) in nonprimiparous women. In the latter, the association between placental FTO and fetal size persisted after further adjusting for placental weight.
Neither cord IGF-I nor insulin was associated with placental FTO in either primiparous or nonprimiparous women.
Placental FTO is unrelated to placental FTO rs9939609 SNP Placentas from the studied women were also genotyped for the rs9939609 SNP in FTO. No significant differences in the expression of FTO in placenta were observed among genotypes of the rs9939609 SNP (FTO expression in TT subjects (n ¼ 51): 0.66 ± 0.32; in TA subjects (n ¼ 68): 0.65±0.32; and in AA subjects (n ¼ 26): 0.63±0.30). No interaction was observed for maternal parity in these results.
Discussion
FTO gene is highly expressed in human term placenta and is related to fetal and placental weight in a maternal paritydependent manner.
Maternal parity is known to influence size at birth. Infants from nonprimiparous pregnancies use to be larger, longer and to have greater head circumferences at birth. 28 In agreement with these authors, infants born to nonprimiparous mothers were larger and had higher cord IGF-I in our study. Placental FTO expression was also higher in these pregnancies, which is in agreement with the purported role of FTO inducing growth. Moreover, in nonprimiparous pregnancies, FTO mRNA was associated with higher fetal weight and length and higher placental weight. Our findings suggest that the mechanisms whereby placental FTO is associated with fetal growth may include both indirect FTO effects, through increased placental weight, and direct FTO effects unrelated to the regulation of placental growth, the latter being supported by the independent associations between FTO gene expression and fetal size. Primiparous pregnancies result in a smaller fetal growth. In these pregnancies, a higher FTO expression was found in smaller placentas, which was in turn associated with a higher fetal-to-placental weight ratio. These observations further support a role for FTO in fetal growth that is independent of the regulation of placental size. In these lightly growthrestricted pregnancies, FTO may also prove to be a regulator of the partitioning between placenta and fetal growth.
Recent data suggest a low heritability for FTO gene expression. 29 We failed to show an association between placental FTO mRNA and either maternal BMI or placental rs9939609 SNP in our study. Taken together, these observations suggest that maternal genetics have no major role in the association between placental FTO and prenatal growth. The present data, however, cannot exclude an increased FTO expression in fetal tissues in association with increased placental gene expression. Although the mechanisms that relate FTO to growth processes remain to be elucidated, sequence analysis predicts that FTO protein contains a double-stranded b-helix fold homologous to those found in Fe(II) and 2OG oxygenases.
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2OG oxygenases are involved in diverse processes, including DNA repair, fatty acid metabolism and posttranslational modifications. 30 According to these authors, the catalytic activity of FTO may regulate the transcription of genes involved in metabolism by nucleic acid demethylation. Given these data, we propose that FTO may similarly have a role in the control of genes related to fetal growth. Data from a most recent manuscript in sheep give support to the results from our study by showing that FTO is highly expressed in placenta in late gestation and is positively related to fetal weight. 31 In conclusion, our data report for the first time on the role of the human placenta as a source of FTO in a representative sample of healthy pregnancies and indicate that placental FTO expression is associated with fetal and placental weight in a maternal parity-dependent manner.
